Figure 4 | Scientific Reports

Figure 4

From: MGMT is frequently inactivated in pancreatic NET-G2 and is associated with the therapeutic activity of STZ-based regimens

Figure 4The alternative text for this image may have been generated using AI.

Tumor shrinkage rates after STZ administration. (A) The maximum shrinkage rate of the target lesion in each STZ-treated patient with positive and negative MGMT expression. (B) The maximum shrinkage effect as judged by RECIST criteria in patients with positive and negative MGMT expression. Maximum shrinkage rate (%) = [(sum of tumor diameters at maximum reduction − baseline diameters)/baseline diameters] × 100 for SD or PR patients. Maximum shrinkage rate (%) = [(sum of tumor diameters at maximum increase − baseline diameters)/baseline diameters] × 100 for PD patients. Statistical significance was determined by Pearson's chi-square test.

Back to article page